Ergoteles LLC Nuvation Bio Inc. Transaction History

Ergoteles LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 10, 2023	SELL	$1.6 - $2.48 $191,728 - $297,178	-119,830 Reduced 81.45%	27,299 $45,000
Q4 2022 Feb 14, 2023	BUY	$1.68 - $2.5 $247,176 - $367,822	147,129 New	147,129 $282,000
Q2 2022 Aug 12, 2022	BUY	$3.24 - $5.85 $1.65 Million - $2.98 Million	510,003 New	510,003 $1.65 Million

158

157M

3.2K

98.7K

Ticker NUVB
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 217,244,000
Market Cap $613M
Description
Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-422, a small molecule inhibitor targeting cyclin-dependent kinase (CDK)2, CDK4, and CDK6. It is also developing NUV-868, a selective oral small molecule BET inhibitor that e...

Get notified when there are updates to the investment portfolio of Ergoteles LLC, based on Form 13F filings with the SEC.

Stay updated on Ergoteles LLC with notifications on news.